Introduction. This paper analyzes the pharmaceutical market for drugs for the treatment of Alzheimer's disease. The aim of the work is to analyze the trigger mechanism for the onset of Alzheimer's disease and the analysis of drugs intended for the treatment of patients with this disease in order to identify the need to create new drugs in this area. Materials and methods. The work used statistical methods, methods of content analysis, as well as analysis of data available in the literature. As a result of the study, it was shown that the mechanisms of development of Alzheimer's disease are the cause of dementia throughout the world. Its symptoms include various stages associated with impaired speech, with an inability to perform motor activities. Currently, the occurrence of the disease is explained by two mechanisms of occurrence: amyloid and glomerular. In the amyloid mechanism, a large role is assigned to β-amyloid, the glomerular mechanism involves continuation inside the cell with the help of a special Tau protein. Discussion: the estimated number of people with dementia in 2020 was 29.23 million in Asia, 12.71 million in Europe, 11.42 million in North America and 5.3 million in Africa. According to the existing and forecast cases of this disease will steadily increase. In this paper, we analyzed two types of drugs: for the treatment of dementia and cholinesterase inhibitors. It has been shown that mainly 3 international non-proprietary names (INN) (Memantine Donepezil + Memantine, Galantamine) are used as drugs for the treatment of dementia, which correspond to 25 trade names, represented in turn by 2 forms of release. Most of the drugs in this group are produced in Russia (67.6%). The second largest production is Germany (8.1%). In third place is Poland (5.4%). The pharmacological group of cholinesterase inhibitors is represented by 6 INNs (Galantamine, Donepezil, Ipidacrine, Neostigmine methyl sulfate, Pyridostigmine bromide, Rivastigmine), corresponding to 15 trade names and 2 forms of release (solution for intravenous and subcutaneous administration and prolonged-release capsules). The share of Russian drugs in this group is 50%, which indicates the priority of domestic manufacturers in this group of drugs. In conclusion, it was shown that despite the fact that there is a priority for domestic manufacturers in the pharmaceutical market, nevertheless, the range of dosage forms is insufficient, which leads to the need to create new dosage forms, in accordance with modern innovative technologies.